Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
-- Patients in Cohort 4 received ADVM-022 high dose 6x1011 vg and prophylactic steroid eye drops --
-- Data from all four cohorts planned by the end of 2020 --
REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of patient dosing in Cohort 4 of OPTIC, a Phase 1 clinical trial, assessing a single intravitreal (IVT) injection of ADVM-022 in patients with wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss in patients over 60 years of age, with a prevalence of approximately 1.2 million individuals in the U.S. and 3 million worldwide.
“The excitement in the retina community around the OPTIC clinical trial and the ADVM-022 program continues to grow,” said Aaron Osborne, MBBS, chief medical officer of Adverum Biotechnologies. “We look forward to presenting data from all four cohorts by the end of this year. Our goal is to deliver a novel one-time intravitreal treatment to patients living with wet AMD as quickly as possible.”
David S. Boyer, M.D., senior partner, Retina-Vitreous Associates Medical Group and adjunct clinical professor of ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, California and investigator in OPTIC added, “Patients enrolled in the OPTIC study have previously required frequent and ongoing anti-VEGF injections to avoid losing vision. The long-term durability beyond 1 year seen with a single intravitreal injection of ADVM-022 in Cohort 1 is unprecedented. ADVM-022 has the potential to transform the treatment paradigm and improve real-world vision outcomes for patients with wet AMD.”
About the OPTIC Phase 1 Trial of ADVM-022 in Wet AMD
Eleven leading retinal centers across the United States (U.S.) are participating in the OPTIC Phase 1 trial for ADVM-022. For more information on the OPTIC Phase 1 clinical trial of ADVM-022 in wet AMD, please visit https://clinicaltrials.gov/ct2/show/NCT03748784.
About ADVM-022 Gene Therapy
In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration granted Fast Track designation for ADVM-022 for the treatment of wet AMD. Adverum is currently evaluating ADVM-022 in the OPTIC Phase 1 clinical trial in patients with wet AMD and the INFINITY Phase 2 trial in patients with DME.
About Wet Age-related Macular Degeneration (AMD)
Wet AMD is a leading cause of vision loss in patients over 60 years of age, with a prevalence of approximately 1.2 million individuals in the U.S. and 3 million worldwide. The incidence of new cases of wet AMD in the U.S. is approximately 150,000 to 200,000 annually, and this number is expected to grow significantly as the country’s population ages.
The current standard-of-care therapy for wet AMD is anti-VEGF intravitreal injections. These are effective but typically require eye injections every 4-12 weeks in order to maintain vision. Compliance with this regimen can be difficult for patients, caregivers, and healthcare systems, leading to undertreatment and resulting in loss of vision.
About Adverum Biotechnologies
Investor and Media Inquiries:
IoT Evolution #TECHSUPERSHOW Expo Hall Open
Keynote Roundtable Discussion